| 000 | 02183cam a2200193 4500500 | ||
|---|---|---|---|
| 005 | 20250112021452.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aMelicine, Sophie _eauthor |
| 700 | 1 | 0 |
_a Gendron, Nicolas _eauthor |
| 700 | 1 | 0 |
_a Darnige, Luc _eauthor |
| 700 | 1 | 0 |
_a Mauge, Laetitia _eauthor |
| 245 | 0 | 0 | _aAntiphospholipid antibodies: What’s new in 2022? |
| 260 | _c2022. | ||
| 500 | _a76 | ||
| 520 | _aAntiphospholipid syndrome (APS) is a clinical-biological entity defined by the combination of thrombotic events and/or obstetric complications and the presence of persistent antiphospholipid antibodies (APLAs) detected by coagulation tests (lupus anticoagulant, LAC) and/or immunological assays (anticardiolipin and anti-glycoprotein-beta-I antibodies). The increased use of direct oral anticoagulants (DOACs) for the treatment of venous thromboembolism (VTE) poses a challenge for hematology laboratories when it comes to diagnosing APS. DOACs interfere with LAC screening and confirmation tests, resulting in a risk of false positive results. To avoid these interferences, several solutions are suggested. Some of them rely on the use of DOAC-reversal systems (activated charcoal tablet, filter system); others on the use of reagents insensitive to DOAC presence in the sample. Detection of anti-phosphatidylserine/prothrombin antibodies may be helpful because they are strongly associated with the presence of LAC and are increasingly recognized as a useful tool in the diagnosis and prognosis of APS. Finally, positivity of LA in the context of a viral infection is frequent and not specific to APS. During the Covid-19 pandemic, many patients developed arterial and/or venous thromboembolism that could suggest testing for APLAs. The link between LAC and a risk of VTE or in-hospital mortality in hospitalized Covid-19 patients was not demonstrated. Moreover, APLAs do not persist after Covid-19. Currently, testing for APLAs in Covid-19 patients is not recommended. | ||
| 786 | 0 | _nAnnales de Biologie Clinique | 80 | 4 | 2022-07-01 | p. 333-343 | 0003-3898 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-annales-de-biologie-clinique-2022-4-page-333?lang=en |
| 999 |
_c136079 _d136079 |
||